201 related articles for article (PubMed ID: 29133219)
1. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial.
Schneider TR; Johns CB; Palumbo ML; Murphy KC; Cahill KN; Laidlaw TM
J Allergy Clin Immunol Pract; 2018; 6(3):825-831. PubMed ID: 29133219
[TBL] [Abstract][Full Text] [Related]
2. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
3. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.
Jerschow E; Edin ML; Chi Y; Hurst B; Abuzeid WM; Akbar NA; Gibber M; Fried MP; Han W; Pelletier T; Ren Z; Keskin T; Roizen G; Lih FB; Gruzdev A; Bradbury JA; Schuster V; Spivack S; Rosenstreich D; Zeldin DC
J Allergy Clin Immunol Pract; 2019; 7(5):1580-1588. PubMed ID: 30580047
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial.
Sommer DD; Rotenberg BW; Sowerby LJ; Lee JM; Janjua A; Witterick IJ; Monteiro E; Gupta MK; Au M; Nayan S
Int Forum Allergy Rhinol; 2016 Apr; 6(4):385-91. PubMed ID: 26751262
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
6. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
7. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
8. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
Mastalerz L; Januszek R; Kaszuba M; Wójcik K; Celejewska-Wójcik N; Gielicz A; Plutecka H; Oleś K; Stręk P; Sanak M
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt B):163-9. PubMed ID: 26209241
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
[No Abstract] [Full Text] [Related]
10. A trial of type 12 purinergic (P2Y
Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma.
Bochenek G; Stachura T; Szafraniec K; Plutecka H; Sanak M; Nizankowska-Mogilnicka E; Sladek K
J Allergy Clin Immunol Pract; 2018; 6(2):528-535. PubMed ID: 28888846
[TBL] [Abstract][Full Text] [Related]
12. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
[TBL] [Abstract][Full Text] [Related]
13. Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.
Sowerby LJ; Patel KB; Schmerk C; Rotenberg BW; Rocha T; Sommer DD
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):27. PubMed ID: 33892819
[TBL] [Abstract][Full Text] [Related]
14. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease.
Cardet JC; White AA; Barrett NA; Feldweg AM; Wickner PG; Savage J; Bhattacharyya N; Laidlaw TM
J Allergy Clin Immunol Pract; 2014; 2(2):208-13.. PubMed ID: 24607050
[TBL] [Abstract][Full Text] [Related]
15. Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.
Jerschow E; Ren Z; Hudes G; Sanak M; Morales E; Schuster V; Spivack SD; Rosenstreich D
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):321-328.e1. PubMed ID: 26822279
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab can inhibit respiratory reaction during aspirin desensitization.
Lang DM; Aronica MA; Maierson ES; Wang XF; Vasas DC; Hazen SL
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):98-104. PubMed ID: 29777744
[TBL] [Abstract][Full Text] [Related]
17. Clinical updates in aspirin-exacerbated respiratory disease.
Laidlaw TM
Allergy Asthma Proc; 2019 Jan; 40(1):4-6. PubMed ID: 30582489
[No Abstract] [Full Text] [Related]
18. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
Stevens WW; Peters AT; Hirsch AG; Nordberg CM; Schwartz BS; Mercer DG; Mahdavinia M; Grammer LC; Hulse KE; Kern RC; Avila P; Schleimer RP
J Allergy Clin Immunol Pract; 2017; 5(4):1061-1070.e3. PubMed ID: 28286156
[TBL] [Abstract][Full Text] [Related]
20. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.
Comhair SAA; Bochenek G; Baicker-McKee S; Wang Z; Stachura T; Sanak M; Hammel JP; Hazen SL; Erzurum SC; Nizankowska-Mogilnicka E
Respir Res; 2018 Oct; 19(1):210. PubMed ID: 30376852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
